Incretin-based therapies
نویسندگان
چکیده
منابع مشابه
Incretin-based therapies
Incretin-based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase-4 inhibitors and the injectable class, the glucagon-like peptide-1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus algorithm for the initiation and adjustment of ther...
متن کاملIncretin-Based Therapies
INTRODUCTION (BY M.A.N.) — Incretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 are new classes of antidiabetic agents first introduced in the years 2005 (exenatide) and 2007 (sitagliptin), respectively. Both use the antidiabetic properties of the incretin hormone, glucagon-like peptide (GLP)-1 (1). This gut-derived peptide hormone not only augments glucose-induced insu...
متن کاملPancreatitis Associated With Incretin-Based Therapies
In recent years, incretin-based therapies such as glucagon-like peptide-1 agonists (GLP-1) and dipeptidyl peptidase-IV inhibitors (DPP-IV) have become important therapeutic options for treatment of type 2 diabetes. Although these agents are considered safe, long-term safety outcome studies are lacking. Theoretically, the combination of these two classes of agents could increase efficacy, but th...
متن کاملDo incretin-based therapies cause acute pancreatitis?
In 2007 a question was raised about the causal relationship between the first of the glucagon-like peptide 1 receptor agonists, exenatide, and pancreatitis, as postmarketing reports of pancreatitis in patients treated with this agent had been received by the Food and Drug Administration (FDA). There had been six reports of hemorrhagic pancreatitis, with two of the cases resulting in death. An u...
متن کاملHistorical Overview of Incretin Based Therapies
The existence of incretins was postulated in the early 20th century when Murce administered duodenal extract in patients with diabetes and demonstrated reduction in glucosuria. However, the identity of the putative incretin factor(s) remained elusive until the purification and characterisation of the first incretin, GIP, was discovered in 1973. GIP is a peptide of 42 amino acids, produced predo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes
سال: 2012
ISSN: 1753-0393
DOI: 10.1111/j.1753-0407.2011.00143.x